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ABSTRACT
Purpose: The F-box protein S-phase kinase-associated
protein 2 (Skp2) positively regulates the G1-S phase transi-
tion by controlling the stability of several G1 regulators,
such as p27Kip1. However, the clinical significance of Skp2
in patients with acute myelogenous leukemia (AML) re-
mains unknown.
Experimental Design: We examined the clinical and
biological significance of Skp2 expression in AML and eval-
uated the relationship between Skp2 and p27Kip1 expres-
sion and phosphatase and tensin homologue (PTEN) phos-
phorylation.
Results: Western blot analysis showed that high Skp2
expression was observed in 57 (57.6%) cases and signifi-
cantly correlated with unfavorable cytogenetics (P  0.035)
but not with age, white blood cell count, serum lactic dehy-
drogenase level, and the French-American-British subtype.
An inverse correlation was not observed between Skp2 and
p27Kip1 expression. However, p27Kip1 protein was prefer-
entially localized to cytoplasm in the high-Skp2-expression
group. The cytoplasmic to nuclear ratio of p27Kip1 expres-
sion was significantly correlated with the levels of Skp2
expression (P < 0.001). The frequency of PTEN phospho-
rylation was significantly higher in the high-Skp2-expres-
sion group compared with the low- Skp2-expression group
(P  0.035). The Skp2 overexpression was significantly as-
sociated with shorter disease-free survival and overall sur-
vival (P 0.0386 and P 0.0369, respectively). Multivariate
analysis showed that Skp2 expression was an independent
prognostic factor both in the disease-free survival and over-
all survival.
Conclusion: These findings suggest that Skp2 expres-
sion is an independent marker for a poor prognosis in AML.
The presence of a positive correlation between Skp2 and
phosphorylated PTEN suggests that an aberration in the
PTEN/Skp2 signaling pathway might be operating in AML.
INTRODUCTION
The importance of the G1-S-phase progression in various
tumors has been highlighted by the frequent observations of
aberrant regulation of molecules involved in this process.
p27Kip1 is a potent inhibitor of the cyclin E–cyclin-dependent
kinase-2 and cyclin A–cyclin-dependent kinase-2, which drive
the cells from the G1 to the S phase (1–2). Although p27Kip1 is
rarely mutated in human cancers, many studies have shown that
the reduced expression of p27Kip1 is frequently observed in
various cancers (3–7). Low p27Kip1 levels are associated with
the high aggressiveness and reduced survival in many cancers
including acute myelogenous leukemia (AML; refs. 3–10).
The expression of p27Kip1 is controlled both at the level of
transcription and by multiple posttranslational mechanisms, in-
cluding the ubiquitin-mediated proteasomal degradation (11–
14). S-phase kinase-associated protein 2 (Skp2) is a member of
the F-box family of the specific substrate-recognition subunit of
the Skp1/Cu11/F-box ubiquitin-protein ligase complexes (15).
Skp2 is required for the ubiquitination and subsequent protea-
somal degradation of p27Kip1 protein (16–18). High levels of
p27Kip1 and free cyclin E expression were observed in the Skp2
knockout cells (19). Recent studies have indicated a possible
relationship between Skp2 and its oncogenic potential. Skp2
expression was increased in the transformed cell lines (15) and
malignant tumors (9, 20–25). Furthermore, a high Skp2 expres-
sion level was significantly correlated with an advanced clinical
stage (9, 24) and a poor prognosis in tumors (9, 23, 24, 26, 27).
The p27Kip1 level was inversely related to the Skp2 level in
various human cancers (9–10, 21–23, 25, 26). Interestingly, this
inverse correlation was not observed in a substantial proportion
of aggressive cancers, although the high levels of Skp2 expres-
sion correlated well with the cell proliferation and disease
progression (27–29). Until now, an evaluation of Skp2 protein
expression in relation to the p27Kip1 expression and the clinical
outcome has not been undertaken in AML.
Skp2 has a complex relationship with the tumor suppressor
protein phosphatase and tensin homologue (PTEN; refs. 30–32).
By dephosphorylating phosphatidylinositol 3,4,5-triphosphate
(PIP3), PTEN antagonizes the phosphatidylinositol 3-kinase
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(PI3-K)-mediated growth-promoting and antiapoptotic path-
ways (33–34). A high frequency of PTEN mutations has been
reported in several human cancers (35). The loss of PTEN also
predisposes the malignant transformation in a variety of tissues
(36). The downstream effectors that mediate the PTEN-induced
growth arrest have been identified, including Akt (37–38) and
p27Kip1 (39). The relationship between Skp2 expression and
the loss of PTEN is particularly interesting in view of the
finding that a deletion of PTEN in mouse fibroblasts leads to
the increased Skp2 levels with concomitant reductions in the
p27Kip1 levels (40). Skp2 expression was inversely correlated
with PTEN expression in prostate cancer (9). These findings
suggest that PTEN functions as a negative regulator of the Skp2
pathway. Therefore, it would be necessary to evaluate the func-
tional implication of PTEN as a regulator of the Skp2 pathway
in AML.
The mutations in the PTEN gene are very infrequent ge-
netic aberrations in myeloid leukemia (41–42). Recently, our
group demonstrated that the COOH-terminal regulatory domain
of the PTEN protein is constitutively phosphorylated in a sub-
stantial proportion of AML cases (43). The phosphorylation of
the PTEN protein was strongly associated with the activation of
the downstream molecules, including Akt and the forkhead
transcription factor in AML cells (43). However, the relation-
ship between Skp2 expression and PTEN phosphorylation has
not been evaluated in AML.
The aim of this study was to examine the expression of the
Skp2 protein and evaluate its correlation with the patient char-
acteristics and clinical outcome in AML. This study also exam-
ined whether or not Skp2 expression is correlated with the
expression and the localization of p27Kip1 protein, and the
constitutive phosphorylation of PTEN protein in AML cells. We
demonstrated for the first time that a high Skp2 expression is
observed in a substantial proportion of AML cases and is
associated with a poor prognosis. Skp2 expression was also
strongly correlated with the mislocalization of the p27Kip1
protein and the constitutive phosphorylation of the PTEN pro-
tein. These findings might provide additional insight into the
molecular pathogenesis and potential therapeutic targets for
adult AML.
MATERIALS AND METHODS
Patients and Treatment. A total of 99 consecutive
adults patients with de novo AML who had not received anti-
leukemia treatment were enrolled in the study. According to the
French-American-British classification (63), four patients had
the M0, 20 patients had the M1, 33 patients had the M2, 19
patients had the M4, 21 patients had the M5 and 2 patients had
the M6 subtype (Table 1). Patients with the M3 subtype of AML
were excluded from this study. All of the patients were treated
according to the first-line induction and consolidation regimens
of Severance Hospital. Eighty-four patients received induction
chemotherapy comprising cytarabine (100 mg/m2/d, continuous
infusion for 7 days) and idarubicin (12 mg/m2/d, i.v. bolus for 3
days). Complete remission was defined as the normalization of
the blood counts and bone marrow morphology along with the
disappearance of all signs of leukemia, lasting for 4 weeks or
longer, in accordance with the recommendations of the National
Cancer Institute-sponsored Workshop (44). All patients achiev-
ing complete remission received the same two courses of mi-
toxantrone-etoposide-cytarabine (MEC) consolidation therapy
consisting of cytarabine (1g/m2/d, i.v. infusion for 2 hours,
every 12 hours for a total of eight times), mitoxantrone (12
mg/m2/d for 3 days), and (etoposide; 100 mg/m2/d for 2 days),
as described previously (45). The patients who relapsed also
received a mitoxantrone-etoposide-cytarabine chemotherapy.
Isolation of Leukemic Cells. In conjunction with the
institutional review board-approved treatment protocol, bone
marrow aspirates were prospectively prepared from the patients
before initiating chemotherapy. The bone marrow was sedi-
mented on a Ficoll-Hypaque (Pharmacia Biotech, Uppsala,
Sweden) density gradient. After washing the mononuclear cells
collected from the upper interface, we performed the T-cell
depletion using a high-gradient magnetic cell separation system/
anti-CD3 monoclonal antibody (Miltenyi Biotech, Auburn, CA)
according to the manufacturer’s instructions. A morphological
evaluation indicated that more than 95% of the isolated cells
were leukemic blasts.
Antibodies and Reagents. The mouse monoclonal anti-
bodies to Skp2 and p27Kip1 were purchased from ZYMED
(San Francisco, CA). The rabbit polyclonal antibodies against
PTEN and phosphorylated PTEN (pPTEN) were obtained from
Cell Signaling Technology (Beverly, MA). The anti-pPTEN
antibody detects PTEN protein that is phosphorylated at the
Ser380/Thr382/Thr383 residues in the COOH-terminal regula-
tory domain. The antihuman -tubulin monoclonal antibody
was acquired from Cedarlane (Ontario, Canada). The horserad-
ish peroxidase-conjugated goat antimouse IgG and horseradish
peroxidase-conjugated goat antirabbit IgG were purchased from
PharMingen (San Diego, CA). Unless indicated otherwise, all
other culture reagents were purchased from Life Technologies,
Inc. (Grand Island, NY).
Cytogenetic Analysis. Chromosomal analysis was per-
formed on the pretreated bone marrow cells. The samples were
processed using short-term unstimulated cultures (24–72 h).
The clonality criteria and descriptions of the chromosomal ab-
errations were in accordance with the International System for
Human Cytogenetic nomenclature. The patients were divided
into three prognostic groups based on the karyotype; the prog-
nostic groups were favorable [t(8;21), inv(16)], intermediate
(normal cytogenetics), and unfavorable (all other abnormali-
ties).
Cell Cycle Analysis. After treatment, the cells were pel-
leted and fixed in 70% ethanol on ice for 1 hour and resus-
pended in 1 ml of a cell cycle buffer (0.38 mM sodium citrate,
0.5 mg/ml RNase A, and 0.01 mg/ml propidium iodide) at a
concentration of 106 cells/ml. Cell cycle analysis was performed
using a FACSCalibur flow cytometer (Becton Dickinson, San
Jose, CA) equipped with CellQuest software (Becton Dickin-
son).
Preparation of Nuclear and Cytoplasmic Fractions.
Cells were subfractionated as described previously (46) with
minor modifications. Cells were pelleted by centrifugation (5
min; 12,000 rpm; 4°C) and incubated in a hypotonic buffer [10
mM HEPES (pH 7.2), 10 mM KCl, 1.5 mM MgCl2, 0.1 mM
EGTA, 20 mM NaF, 100 M Na3VO4, and 0.1% protease
inhibitor cocktail (Sigma Chemical, St. Louis, MO)] for 30
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minutes at 4°C while rocking. Cells were broken using a
Dounce homogenizer (30 strokes), after which nuclei were
pelleted by centrifugation (10 min; 3,500 rpm; 4°C). The nuclei-
free supernatant was subjected to a second centrifugation at
10,000  g for 45 minutes at 4°C to separate membrane (pellet)
from cytosolic (supernatant) fractions. Nuclear pellets (above)
were resuspended in nuclear lysis buffer [10 nM Tris-HCl (pH
7.5), 150 mM NaCl, 5 mM EDTA, and 1% Triton X-100] and
were incubated for 1 minute in a sonicating water bath, followed
by a 30-min incubation at 4°C while rocking. Twenty milli-
grams of total cytosolic and nuclear protein were analyzed by
Western blot.
Western Blotting. The cells were dissolved in 100 l of
a SDS-PAGE sample buffer containing -mercaptoethanol at a
final concentration of 3  106 cells. The lysates were sonicated
for 15 seconds with a Vibra Cell Sonicator, boiled for 10
minutes, and further analyzed by Western blotting. The protein
yields were quantified using the Bio-Rad Dc protein assay kit
(Hercules, CA) and equivalent amounts of the protein (40 g)
were applied to the 15% acrylamide gels. The proteins were
separated by SDS-PAGE and were transferred to nitrocellulose
membranes (Amersham Biosciences, Piscataway, NJ). The
membranes were blocked at room temperature with 3% bovine
serum albumin in TBST (1 Tris-buffered saline, 0.1% Tween
20) for 16 h. After washing twice in TBST, the membranes were
incubated with the primary antibodies for 2 hours at room
temperature. The membranes were then washed four times in
TBST and were incubated with the relevant horseradish perox-
idase-conjugated secondary antibodies (1:3000 dilution with 3%
bovine serum albumin in TBST) for 1 h. After washing four
times in TBST, the reactive proteins were visualized by an
enhanced chemiluminescence detection system (Amersham
Biosciences). Densitometry was performed using the Molecular
Dynamics Imaging system and ImageQuant 3.3 software (Am-
ersham Biosciences) to quantify the relative amounts of the
protein detected on Western blots.
Statistical Analysis. To perform the quantitative analy-
sis, the Skp2 protein expression level in the AML cells (L) was
evaluated by normalization as follows: corrected L (Lc)  Skp2
(L)/-tubulin (L) as determined by Western blot analysis. The
patients were divided into two groups (high and low) based on
the median Lc value of Skp2 expression in bone marrow mono-
nuclear cells of 10 normal candidates. The comparisons among
characteristics of the subgroups were made using a 2 test for
the binary variables and a Mann-Whitney test for the continuous
variables. The linear regression analysis and two-tailed Student
t test were used to assess the association between Skp2 and
p27Kip1 protein expression. The 2 test was used to determine
the relationship of Skp2 with pPTEN. The disease-free survival
and overall survival probabilities were calculated using the
Kaplan-Meier method. The log-rank statistic was used to test the
difference in survival times between the groups. In addition to
the Skp2 expression, the white blood cell count, age, and cyto-
genetics were analyzed in the univariate and multivariate anal-
ysis. Multivariate analysis was used to test for the independent
prognostic significance of variables using the Cox proportional
hazards regression model. The patients alive, and still in remis-
sion at last follow-up examination, were censored in the analy-
sis. All of the calculations were performed using the SPSS
software, version 11.0.1 (SPSS Inc, Chicago, IL). A P-value of
0.05 was considered significant.
RESULTS
Skp2 Protein Expression in AML Cells. The expres-
sion levels of the Skp2 protein in the AML cells varied among
the patients (Fig. 1A). Western blot analysis revealed that Skp2
protein expression was present in 74 (74.7%) of the 99 cases. To
perform the quantitative analysis, the Skp2 protein expression
level was determined in the AML cells (L) by normalization as
follows: Lc  Skp2 (L)/-tubulin (L), as determined by Western
blot analysis. In this study, the Lc ranged from 0 to 840.4. In the
practical evaluations, a cutoff value (Lc, 0.70) was set for these
protein expression levels in the AML cells, because the median
Lc level of Skp2 protein expression in the 10 normal bone
marrow mononuclear cells was 0.70 (range, 0–1.02). Using this
cutoff value, we classified the AML cases into two groups, a
Fig. 1 Western blot analysis of Skp2 and p27Kip1 protein expression
in the representative AML and normal bone marrow (BM) samples. A,
the levels of Skp2 protein expression were variable according to the
samples. -tubulin was used for control of protein concentration on
Western blot. UPN represents unique patient number. B, the subcellular
localization and expression of the p27Kip1 protein in relation to the
Skp2 protein expression were analyzed by SDS-PAGE of the nuclear
and cytoplasmic fractions of the cell lysates as described in Materials
and Methods. C, the mean C/N ratio of p27Kip1 protein was signifi-
cantly higher in the AML cases showing a high Skp2 expression
compared with the cases showing a low level of Skp2 expression (P 
0.001). CI, confidence interval.
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high-expression group [n  57 (57.6%)] and a low-expression
group [n  42 (42.4%)].
The association between Skp2 expression and the various
clinical parameters in AML were evaluated. As shown in Table
1, there was no significant difference regarding age, sex, white
blood cell count, and the French-American-British subtype. A
statistically significant correlation was observed between Skp2
expression and unfavorable cytogenetics (2 test, P  0.035).
Cell cycle analysis demonstrated that the fraction of cells in the
G0-G1 phase was higher in the AML cells showing a high Skp2
expression (85.2  18.1%) compared with the cells showing a
low Skp2 expression (75.9  24.0%) without statistical signif-
icance (P  0.435; Table 2). Likewise, the Skp2 expression
levels were not correlated with the fractions of the cells in the
G2-M or S phase, respectively (Table 2).
Association of Skp2 and p27Kip1 Protein Expression in
AML. The relationship between Skp2 and p27Kip1 protein
expression was examined. Linear regression analysis was used
to assess the association between the Skp2 and p27Kip1 expres-
sion levels. Overall, there was no inverse correlation between
Skp2 and p27Kip1 protein expression (r  0.082, P  0.613;
data not shown). The subcellular localization of the p27Kip1
protein with respect to Skp2 expression was then examined.
Western blotting of the fractionated cell lysates demonstrated
that the subcellular localization of the p27Kip1 was predomi-
nantly cytoplasmic in the group with high Skp2 expression
level. In contrast, the p27Kip1 protein mainly located in the
nucleus in the group with low Skp2 expression (Fig. 1B). To
analyze the extent of subcellular localization of the p27Kip1
protein in relation to Skp2 protein expression, we estimated the
cytoplasmic to nuclear (C/N) ratio of p27Kip1 protein expres-
sion. The C/N ratio of p27Kip1 localization ranged from 0 to
127.21. The mean C/N ratio of p27Kip1 protein of the group
showing high levels of Skp2 expression was significantly higher
than that of the group showing low levels of Skp2 expression
(3.35  1.99 versus 20.11  16.06, P  0.001; Fig. 1C).
Correlation of Skp2 Expression with PTEN Phospho-
rylation in AML. The status of PTEN phosphorylation in
relation to Skp2 protein expression in the AML cells was next
examined. The constitutive phosphorylation of PTEN protein
was demonstrated in the majority of AML cases with high Skp2
expression (Fig. 2A). The frequency of PTEN phosphorylation
was significantly higher in the group with high Skp2 protein
expression (42 cases; 73.7%) compared with the cases with low
Skp2 expression (22 cases; 52.4%; P  0.035; Fig. 2B). How-
ever, Skp2 expression was not correlated with the levels of
PTEN expression itself (Fig. 2B).
Prognostic Significance of Skp2 Expression in AML.
As shown in Table 1, the complete remission rate in the high
Skp2 expression group was similar to that in the low Skp2
expression group (81.6% versus 91.4%, P  0.215). However,
survival analysis using the Kaplan-Meier Method demonstrated
that the high Skp2 expression group showed a significantly
shorter disease-free survival compared with that of the low Skp2
expression group (Fig. 3A; P  0.0386 by log-rank test). The
overall survival rate was also significantly lower in the high
Skp2 expression group compared with the low Skp2 expression
group (Fig. 3B; P 0.0369). The disease-free survival estimates
at 5 years for the patients with or without Skp2 overexpression
were 29.4% (SE  11.6%) and 57.9% (SE  15.7%), respec-
tively (P  0.0386; Fig. 3A). The overall survival estimates at
5 years for the patients with or without Skp2 overexpression
were 15.8% (SE  6.8%) and 51.9% (SE  10.8%), respec-
tively (P  0.0369; Fig. 3B). Univariate analysis revealed that
neither white blood cell count nor cytogenetics was a prognostic
variable in our AML cases (Table 3). However, the Skp2 ex-
pression level was a strong prognostic factor for disease-free
survival and overall survival. Multivariate analysis also did not
Table 2 Cell cycle analysis according to Skp2 expression levels
Skp2 expression
PLow (n  42) High (n  57)
G0-G1 75.9  24.0% 85.2  18.1% NS
G2-M 11.9  17.6% 10.9  19.9% NS
S phase 15.7  22.3% 8.5  17.1% NS
Abbreviation: NS, not significant.
Table 1 Patient characteristics and complete remission (CR) rate according to Skp2 expression levels
Skp2 expression*
PLow (n  42) High (n  57)
Age (y), median (range) 45 (15–71) 44 (15–80) NS
Sex (M/F) 24/18 25/32 NS
WBC (109/L), median (range) 15.4 (0.6–238.0) 23.3 (1.2–253.8) NS
LDH (IU/L), median (range) 705 (362–7260) 658 (156–9260) NS
FAB classification NS
M0, M1, M2 22 35
M4, M5 19 21
M6, M7 1 1
Cytogenetics 0.035†
Favorable 6 4
Intermediate 26 27
Unfavorable 10 26
CR rate 91.4% (32/35) 81.6% (40/49) NS
Abbreviations: NS, not significant; WBC, white blood cell(s); LDH, lactic dehydrogenase; FAB, French-American-British (classification).
* Skp2 expression 	Lc  Skp2 (L)/-tubulin (L)
, where L is expression level in the AML cells; low, Lc  0.7; high, Lc  0.7.
† Unfavorable versus non-unfavorable (favorable and intermediate).
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confirm the prognostic value of the white blood cell count nor of
cytogenetics in the enrolled AML cases (Table 4). In contrast,
Skp2 expression remained as an independent prognostic factor
of disease-free survival [relative risk (95% confidence inter-
val)  2.797 (1.038–7.535), P  0.042], and the overall sur-
vival [relative risk (95% confidence interval)  1.927 (1.040–
3.569), P  0.037] (Table 4). These findings suggest that Skp2
expression is an independent marker of a poor prognosis in adult
AML.
DISCUSSION
This study demonstrated that the high levels of Skp2 pro-
tein expression were observed in a substantial proportion of
AML cases and were significantly correlated with a poor prog-
nosis. Furthermore, it was shown for the first time that Skp2
expression was positively correlated with the constitutive phos-
phorylation of the COOH-terminal regulatory domain of the
PTEN protein, along with the cytoplasmic localization of
p27Kip1 protein in AML cells.
This study supports a growing body of evidence demon-
strating the role of Skp2 in an oncogenic process (21–23, 25,
26). Because Skp2 is required for the ubiquitination and pro-
teasomal degradation of p27Kip1 protein (16–18), the deregu-
lation of Skp2 may contribute to the neoplastic transformation
through accelerated p27Kip1 proteolysis. The Skp2-transfected
cell lines expressed low levels of p27Kip1, and showed high
levels of proliferation activity and of resistance to apoptosis and
a high tumor-invasion potential (19, 26). Therefore, a low
p27Kip1 expression in malignant cells may be caused by an
increased expression of Skp2. Indeed, there was an inverse
Fig. 3 Kaplan-Meier survival
curve for disease-free survival
and overall survival rate of pa-
tients with AML according to
the levels of Skp2 protein ex-
pression. High levels of Skp2
protein expression were signif-
icantly associated with lower
disease-free survival (A) and
overall survival rates (B; P 
0.0386 and P  0.0369, respec-
tively). The log-rank statistic
was used to test the difference
in survival times between the
groups.
Fig. 2 A, Western blot analy-
sis of Skp2, PTEN, and pPTEN
protein expression in the repre-
sentative AML samples. Levels
of protein loading were visual-
ized by stripping the membrane
and reprobing with an antibody
for -tubulin. B, the PTEN
(left) and pPTEN (right) ex-
pression according to levels of
Skp2 expression. The fre-
quency of PTEN phosphoryla-
tion was significantly higher in
the high Skp2 expression group
compared with the low Skp2
expression group (P  0.035).
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correlation between the p27Kip1 and Skp2 expression in the
various human cancers (9–10, 21–23, 25, 26).
However, an inverse correlation between the Skp2 and
p27Kip1 protein expression was not observed in our AML
cases. This finding was in agreement with the recent reports
showing that an inverse correlation between these proteins was
not observed in a substantial proportion of aggressive cancers,
although high Skp2 level correlated well with the extent of cell
proliferation and disease progression (27–29). The lack of an
inverse correlation suggests that additional molecular events
associated with the tumorigenic properties of Skp2 (22, 25) or
the aberrant regulation of the p27Kip1 activity (47) may be
operating in AML.
It was suggested that the oncogenic potential of Skp2 is not
restricted to p27Kip1 proteolysis (17, 22, 25). The forced ex-
pression of Skp2 in the quiescent fibroblasts induced DNA
synthesis (17). Skp2 cooperated with N-Ras in the tumorigen-
esis of a T-cell lymphoma in a transgenic mice model (25).
Rodent fibroblasts primarily transformed by both Skp2 and
H-Ras gene transfection could form tumors in nude mice (22).
The Skp2-transfected gastric carcinoma cell lines showed sig-
nificantly higher growth rates, invasion potential, and resistance
to an apoptotic induction by chemotherapeutic agents (26).
These findings suggest that Skp2 plays an important role in
human oncogenesis and in the modulation of the phenotype of
malignant tumors. However, the leukemogenic potential of
Skp2 itself remains to be determined in AML.
In addition to degradation, p27Kip1 activity appears to be
altered by the intracellular localization or sequestration. In tu-
mors with abundant p27Kip1 expression, the protein is often
mislocalized to the cytoplasm (48–50). Because the growth-
restraining activity of p27Kip1 depends on its nuclear localiza-
tion, the mislocalization effectively abrogates the p27Kip1 in-
hibitory activity (48, 51–54). In fact, cytoplasmic p27Kip1
localization seems to directly correlate with a poor long-term
survival and the tumor grade of esophagus and breast carcinoma
(50, 55–57). Although an inverse correlation between Skp2 and
the p27Kip1 protein was not observed in our AML cases, the
high Skp2 level was found to be significantly associated with
the extent of cytoplasmic localization of p27Kip1 protein. The
C/N ratio of p27Kip1 protein significantly correlated with the
level of Skp2 protein expression in AML. These findings sug-
gest that the molecular mechanism, which is involved in the
increased expression of Skp2, is also closely associated with the
mislocalization of p27Kip1 protein in AML.
The mechanism by which the Skp2 protein expression is
increased in AML cells needs to be understood. Skp2 expression
is usually cell cycle dependent; it is low in the G1 phase,
increases in the S phase, and declines afterward (16, 19, 58).
However, in this study, the cell cycle distribution was not
different in relation to Skp2 expression. This finding is in line
with the finding that p27Kip1 expression does not seem to
reflect the cell cycle status of AML in this study, as many
investigators have pointed this out in other types of cancer (59).
It was also previously shown that the levels of Skp2 protein are
not cell cycle dependent in malignant lymphoma (10). These
findings suggest that the dysregulation of the cell cycle cannot
explain the aberrant expression of Skp2 protein in AML cells.
PTEN regulates the ubiquitin-dependent Skp2-mediated
p27Kip1 degradation (40). A deletion of PTEN in mouse fibro-
blasts led to increased levels of Skp2 with concomitant reduc-
tions in the p27Kip1 levels (40). Skp2 was down-regulated by
the expression of the wild-type PTEN or by exposure to the
PI3-K inhibitor in the human glioblastoma cell line U87MG
(40). Skp2 expression is inversely correlated with PTEN expres-
sion in prostate cancer cells (9). These findings suggest that
PTEN functions as a negative regulator of the Skp2 pathway.
However, it has been reported that mutations in the PTEN gene
are very infrequent genetic aberrations in myeloid leukemia
(41–42). Loss of heterozygosity analysis and polymerase chain
reaction single-strand conformation polymorphism (PCR-
SSCP) of the entire coding region showed that none of the AML
cases had a loss of heterozygosity or a mutation (41). We
observed no correlation between the PTEN and Skp2 expression
levels in AML cells.
It was shown that the phosphorylation of the serine and
threonine residues in the COOH-terminal regulatory domain of
PTEN protein regulates both PTEN stability and PTEN enzy-
Table 3 Univariate analysis of age, white blood cell count (WBC),
cytogenetics, and Skp2 expression status for complete remission (CR)
rate, disease-free survival (DFS), and overall survival (OS) in
AML patients
P*
CR DFS OS
Age (y) 60 vs. 60 1.0 0.6815 0.0126
WBC (109/L), 30 vs. 30 0.192 0.4519 0.8996
Cytogenetics, non-unfavorable vs.
unfavorable
0.744 0.6187 0.7413
Skp2 expression (Lc value),† low vs. high 0.184 0.0386 0.0369
* Log-rank test.
† Skp2 expression 	Lc  Skp2 (L)/-tubulin (L)
, where L is
expression level in the AML cells.
Table 4 Multivariate analysis of disease free survival (DFS) and overall survival (OS) in AML patients
DFS OS
P RR (95% CI) P RR (95% CI)
Age (y), 60 vs. 60 0.371 1.653 (0.550–4.968) 0.010 2.174 (1.203–3.936)
WBC ( 109/L), 30 vs. 30 0.495 0.749 (0.326–1.720) 0.786 0.9270 (0.538–1.598)
Cytogenetics, non-unfavorable vs. favorable 0.754 0.873 (0.374–2.041) 0.920 1.030 (0.581–1.826)
*Skp expression (Lc value), low vs. high 0.042 2.797 (1.038–7.535) 0.037 1.927 (1.040–3.569)
Abbreviations: RR, relative risk; CI, confidence interval.
* Skp2 expression 	Lc  Skp2 (L)/-tubulin (L)
, where L is expression level in the AML cells.
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matic activity (60–61). The PTEN phosphorylation keeps the
PTEN stable but makes it less active toward its substrate, PIP3
(62). Recently, we demonstrated that PTEN protein is constitu-
tively phosphorylated in a substantial proportion of AML cases
(43). PTEN phosphorylation was significantly associated with
Akt phosphorylation and the activation of Akt downstream (43).
The underlying mechanism for the constitutive PTEN phospho-
rylation in AML remains unclear. Because it was demonstrated
that a key enzyme regulating the phosphorylation of the COOH-
terminal regulatory domain of PTEN seems to be the protein
kinase casein kinase 2 (62), the casein kinase 2 activity of the
AML cells in relation to PTEN phosphorylation needs to be
evaluated. In this study, PTEN phosphorylation was strongly
associated with the levels of Skp2 expression, but not with
p27Kip1 protein. Because the phosphorylation of the PTEN
protein is highly associated with Akt phosphorylation (43),
PTEN phosphorylation is meant to be closely involved in the
regulation of Skp2 expression via the PI3-K/Akt pathway. If the
specific kinase that regulates PTEN phosphorylation is identi-
fied, the direct contribution of PTEN phosphorylation to the
Akt/protein kinase-B–mediated Skp2 expression will be under-
stood.
This study demonstrated that the high Skp2 protein expres-
sion is significantly associated with poor prognostic features in
AML. The complete remission rate was not different according
to the levels of Skp2 expression. However, the disease-free
survival and overall survival were significantly shorter in AML
cases showing high levels of Skp2 expression compared with
the cases with low levels of Skp2 protein. Multivariate analysis
using the Cox proportional hazard model revealed that Skp2
protein expression level is an independent prognostic factor for
both disease-free survival and overall survival in the whole
cohort.
In conclusion, we demonstrated for the first time that Skp2
overexpression is an independent prognostic factor in AML. In
a majority of AML cases showing high levels of Skp2 expres-
sion, the p27Kip1 protein was preferentially localized to the
cytoplasm, suggesting that an aberrant regulatory pathway is
operating in the Skp2-mediated p27Kip1 proteolysis in AML. In
addition, the finding that Skp2 expression is significantly cor-
related with the constitutive phosphorylation of the PTEN pro-
tein suggests that the pPTEN-Skp2 axis may be a promising
therapeutic target for adult AML.
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